Theresa Amoloja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Theresa Amoloja has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alex Silberzweig
Department of Dermatology, Northwell, New Hyde Park, USA
1 shared publication - Amit G. Pandya
Palo Alto Foundation Medical Group, 401 Old San Francisco Road, Sunnyvale, CA, 94086, USA
1 shared publication - Amit Garg
Northwell, New Hyde Park, USA
1 shared publication Amy Moskop
1 shared publication- Andrew Strunk
Northwell, New Hyde Park, USA
1 shared publication - Dana Britt DiBenedetti
Patient-Centered Outcomes Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5485-5495
Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa
Introduction The risk of thromboembolism in patients with hidradenitis suppurativa (HS) has not been established. This study aimed to estimate the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) among adults with HS and demographic subgroups. Methods This retrospective cohort study was conducted between January 1, 2017, and December 31, 2024, using a health insurance claims database (Optum Clinformatics DataMart) in the US. Adults aged ≥ 18 years with an outpatient visit linked to a diagnosis of HS or any other diagnosis (controls) were eligible. Patients with prior diagnosis of either outcome or associated conditions were excluded. The primary outcomes evaluated were new-onset DVT and PE. Results Mean (SD) age was 43 (16) years for eligible patients with HS (n = 44,520) and 54 (19) years for control patients (n = 3,792,627). Incidence of DVT was 3.0 (95% CI 2.5–3.4) and 3.5 (95% CI 3.4–3.5) per 1000 person-years (PY) in patients with HS and controls, respectively. Incidence of PE was 2.4 (95% CI 2.0–2.8) and 2.2 (95% CI 2.2–2.3) per 1000 PY in patients with HS and controls, respectively. In demographics-adjusted analyses, standardized incidence ratios for DVT and PE were 1.42 (95% CI 1.23–1.65) and 1.78 (95% CI 1.50–2.10), respectively. Comorbidity-adjusted hazard ratios for DVT and PE were 1.12 (95% CI 0.97–1.31) and 1.35 (95% CI 1.14–1.60), respectively. Incidence of DVT was higher in patients with HS by a factor of 1.5–2.9 for age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.5 to 8.8 per 1000 PY. Incidence of PE was higher in patients with HS by a factor of 1.5–3.2 across age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.0 to 5.4 per 1000 PY. Conclusion Patients with HS have a significantly higher incidence of both DVT and PE relative to demographically similar patients without HS. This information may support counseling on risk mitigation strategies and safety monitoring during treatment and may provide context for observed (versus expected) thrombotic events in clinical trials for HS.
- 10 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5485-5495
Open AccessIncidence of Deep Vein Thrombosis and Pulmonary Embolism in Patients with Hidradenitis Suppurativa
Introduction The risk of thromboembolism in patients with hidradenitis suppurativa (HS) has not been established. This study aimed to estimate the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) among adults with HS and demographic subgroups. Methods This retrospective cohort study was conducted between January 1, 2017, and December 31, 2024, using a health insurance claims database (Optum Clinformatics DataMart) in the US. Adults aged ≥ 18 years with an outpatient visit linked to a diagnosis of HS or any other diagnosis (controls) were eligible. Patients with prior diagnosis of either outcome or associated conditions were excluded. The primary outcomes evaluated were new-onset DVT and PE. Results Mean (SD) age was 43 (16) years for eligible patients with HS (n = 44,520) and 54 (19) years for control patients (n = 3,792,627). Incidence of DVT was 3.0 (95% CI 2.5–3.4) and 3.5 (95% CI 3.4–3.5) per 1000 person-years (PY) in patients with HS and controls, respectively. Incidence of PE was 2.4 (95% CI 2.0–2.8) and 2.2 (95% CI 2.2–2.3) per 1000 PY in patients with HS and controls, respectively. In demographics-adjusted analyses, standardized incidence ratios for DVT and PE were 1.42 (95% CI 1.23–1.65) and 1.78 (95% CI 1.50–2.10), respectively. Comorbidity-adjusted hazard ratios for DVT and PE were 1.12 (95% CI 0.97–1.31) and 1.35 (95% CI 1.14–1.60), respectively. Incidence of DVT was higher in patients with HS by a factor of 1.5–2.9 for age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.5 to 8.8 per 1000 PY. Incidence of PE was higher in patients with HS by a factor of 1.5–3.2 across age subgroups between 45 and 74 years, with absolute incidence rates ranging from 3.0 to 5.4 per 1000 PY. Conclusion Patients with HS have a significantly higher incidence of both DVT and PE relative to demographically similar patients without HS. This information may support counseling on risk mitigation strategies and safety monitoring during treatment and may provide context for observed (versus expected) thrombotic events in clinical trials for HS.
- Open Access
- 31 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data
- 31 July 2026
- Published by Elsevier in Transplantation and Cellular Therapy
Open AccessCytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data
- Open Access
- 5 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2467-2478
Assessing Participants’ Experiences with Vitiligo from Patient Interviews
Introduction Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments. Here, we describe the burden of vitiligo and opinions on what constitutes meaningful change among participants of two qualitative interview studies. Methods Qualitative interviews were conducted with a subgroup of adolescent and adult participants with vitiligo from two pivotal phase 3 clinical trials of ruxolitinib cream (Study 1) and a real-world panel (Study 2). Participants were asked about their disease burden, treatment goals, importance of facial/body improvement (treatment satisfaction: scale range 0–10), and meaningfulness of change (yes/no). Results A total of 36 participants from Study 1 and 23 from Study 2 were interviewed. In Study 1, the highest degree of impact was on reduced self-esteem (facial lesions, 62.5%; body lesions, 55.6%), social inhibition (facial lesions, 65.6%; body lesions, 61.1%), and sun sensitivity (facial lesions, 31.3%; body lesions, 55.6%). Most participants (83.3%) reported that facial improvement was equally (36.1%) or more important (47.2%) than body improvement, with mean treatment satisfaction of 8.1 and 6.9, respectively. Meaningful change was reported by 83.3% and 92.9% of participants with 50–74% and ≥ 75% improvement per the facial Vitiligo Area Scoring Index, respectively, and by 82.6% of participants with ≥ 25% improvement per the total Vitiligo Area Scoring Index per Study 1 outcomes at Week 24. In Study 2, most (82.6%) participants felt that the noticeability of their vitiligo affected their behavior. Nearly all (87.0%) said that an ideal treatment would repigment or return natural color to their facial skin; 56.5% considered ≥ 50% facial repigmentation to be the smallest meaningful improvement. Conclusions Participants from both qualitative interviews expressed substantial psychosocial burden. Repigmentation in both facial and body vitiligo were important, with meaningful change determined to be ≥ 50% facial repigmentation and ≥ 25% body repigmentation.
- 5 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2467-2478
Open AccessAssessing Participants’ Experiences with Vitiligo from Patient Interviews
Introduction Vitiligo is an autoimmune disease, causing skin depigmentation. Individuals with vitiligo incur substantial psychosocial burden and have expressed frustration with their treatments. Here, we describe the burden of vitiligo and opinions on what constitutes meaningful change among participants of two qualitative interview studies. Methods Qualitative interviews were conducted with a subgroup of adolescent and adult participants with vitiligo from two pivotal phase 3 clinical trials of ruxolitinib cream (Study 1) and a real-world panel (Study 2). Participants were asked about their disease burden, treatment goals, importance of facial/body improvement (treatment satisfaction: scale range 0–10), and meaningfulness of change (yes/no). Results A total of 36 participants from Study 1 and 23 from Study 2 were interviewed. In Study 1, the highest degree of impact was on reduced self-esteem (facial lesions, 62.5%; body lesions, 55.6%), social inhibition (facial lesions, 65.6%; body lesions, 61.1%), and sun sensitivity (facial lesions, 31.3%; body lesions, 55.6%). Most participants (83.3%) reported that facial improvement was equally (36.1%) or more important (47.2%) than body improvement, with mean treatment satisfaction of 8.1 and 6.9, respectively. Meaningful change was reported by 83.3% and 92.9% of participants with 50–74% and ≥ 75% improvement per the facial Vitiligo Area Scoring Index, respectively, and by 82.6% of participants with ≥ 25% improvement per the total Vitiligo Area Scoring Index per Study 1 outcomes at Week 24. In Study 2, most (82.6%) participants felt that the noticeability of their vitiligo affected their behavior. Nearly all (87.0%) said that an ideal treatment would repigment or return natural color to their facial skin; 56.5% considered ≥ 50% facial repigmentation to be the smallest meaningful improvement. Conclusions Participants from both qualitative interviews expressed substantial psychosocial burden. Repigmentation in both facial and body vitiligo were important, with meaningful change determined to be ≥ 50% facial repigmentation and ≥ 25% body repigmentation.
- 1 November 2021
- Published by Elsevier in Leukemia Research
- Vol. 110, 106711
Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice
- 1 November 2021
- Published by Elsevier in Leukemia Research
- Vol. 110, 106711
Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice